Wells Fargo raised the firm’s price target on C4 Therapeutics to $7 from $6 and keeps an Equal Weight rating on the shares. The firm says additional data for CFT7455 and early CFT1946 data cold be sources of upside for shares in the second half of 2024, the analyst tells investors in a research note. The recent move is pricing in a fair amount optimism on limited data, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CCCC:
- New Debt & Financing Risk for C4 Therapeutics, Inc. – What’s the Latest?
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics upgraded to Neutral from Underweight at JPMorgan
- C4 Therapeutics call volume above normal and directionally bullish
- C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
